Press GreenLight Biosciences in the News July 21, 2021 –– Blog Kimberley Warren welcomed as SVP Business Development, Human Health May 22, 2021 –– Blog The Economist: RNA for Bees and Crops April 15, 2021 –– Blog GenEdge: GreenLight Strives for Global RNA Equity April 11, 2021 –– Blog The National: Africa needs to be self-reliant in vaccine production April 7, 2021 –– Blog Amin Khan welcomed as Chief Scientific Officer, Human Health April 1, 2021 –– Blog Financial Times: How to vaccinate the world March 29, 2021 –– Blog GreenLight partners with Fraunhofer IME March 26, 2021 –– Blog A blueprint to vaccinate the world March 23, 2021 –– Blog The Economist: Novel vaccines performed well March 17, 2021 –– Blog Nature: Innovators target vaccines for variants March 9, 2021 –– Blog BioSpace: Feasibility study for powder form of Covid vaccine March 3, 2021 –– Blog Vox: Lipid nanoparticles are essential to Covid vaccines February 27, 2021 –– Blog CNN: Critical component for Covid-19 vaccines is in short supply February 21, 2021 –– Blog Washington Post: scarcity of biotech ingredients February 11, 2021 –– Blog Elemental: All about mRNA February 6, 2021 –– Blog The Economist: Covid-19 vaccine resource difficulties February 4, 2021 –– Blog Business Insider: GreenLight named as one of six biotechs VCs are watching January 26, 2021 –– Blog Financial Times: If Covid vaccines stop working, how quickly can drugmakers respond? January 22, 2021 –– Blog Business Journal: Boston firms developing Covid vaccines January 15, 2021 –– Blog STAT Opinion: Businesses across the vaccine supply chain must work together to make Covid-19 vaccines January 13, 2021 –– Blog Financial Times: Get vaccine new variant ready January 12, 2021 –– Blog Mail Online: Vaccine roll out issues January 12, 2021 –– Blog Financial Times: Vaccine makers race to fix vaccine supply issues December 9, 2020 –– Blog Technology Review: What are the Pfizer covid-19 vaccine ingredients? December 4, 2020 –– Blog Financial Times: Vaccine manufacturing delays leave UK with fewer vaccines than hoped December 3, 2020 –– Blog Investors Business Daily: Vaccine manufacturing challenge November 25, 2020 –– Blog CNBC: The challenges of Covid-19 vaccine production for the masses November 25, 2020 –– Blog BioSpace: Harnessing Nature for Faster mRNA Vaccine Manufacturing November 20, 2020 –– Blog Wired: Manufacturing enough Covid-19 vaccine is a logistical nightmare November 15, 2020 –– Blog Daily Mail: Suppliers of vaccine materials do not have capacity November 12, 2020 –– Blog Metro: How the Covid vaccine could transform the world November 12, 2020 –– Blog Fortune: If we don’t vaccinate the world quickly, our COVID efforts will be a waste October 21, 2020 –– Blog Unherd: Will a vaccine stop Covid? October 1, 2020 –– Press GreenLight Biosciences welcomes Charu Manocha as Chief People Officer BOSTON, October 1, 2020 – GreenLight Biosciences, Inc., an integrated life sciences company developing RNA-based products for plant health, human health and animal health, today announced Charu Manocha as the company’s new Chief People Officer. September 15, 2020 –– Blog GreenLight Biosciences Receives $3.3 Million Grant BOSTON, Sept. 15, 2020 — GreenLight Biosciences has received a $3.3 million grant from the Bill & Melinda Gates Foundation to develop new mRNA-based gene therapies for Sickle Cell Disease and other global health challenges. June 16, 2020 –– Press GreenLight Supercharges Efforts with $102M in Funding BOSTON, June 16, 2020 – GreenLight Biosciences today announced it has raised an oversubscribed $102 million round of funding from new and existing investors to rapidly expand production of its RNA products for agricultural and life sciences applications, including an expansion into new RNA-based therapies. May 12, 2020 –– Press $17M Raised for COVID-19 Vaccine Manufacturing BOSTON, May 12, 2020 /PRNewswire/ — GreenLight Biosciences today announced it has closed an oversubscribed $17M special purpose funding round from new and existing investors to build out its scalable mRNA production capability targeting the production of billions of doses of COVID-19 vaccine. September 19, 2019 –– Press GreenLight CEO Nominated for the Belisario Domínguez Medal of Honor MEDFORD, Mass., Sept. 19, 2019 /PRNewswire/ — Andrey Zarur, Ph.D., co-founder, president and CEO of GreenLight Biosciences, Inc., has been nominated as a candidate for the Medalla de Honor “Belisario Domínguez” del Senado de la República (Belisario Domínguez Medal of Honor) by the Mexican Senate. June 11, 2019 –– Press GreenLight Welcomes Susan Keefe as CFO MEDFORD, Mass., June 11, 2019 /PRNewswire/ — GreenLight Biosciences, Inc., the bio-performance company developing RNA-based solutions for agriculture and pharmaceutical applications, welcomes Susan Keefe as chief financial officer to lead the company\’s financial strategy and facilitate its growth plan. May 31, 2019 –– Press GreenLight Boosts R+D Capabilities with Key Hires MEDFORD, Mass., May 31, 2019 /PRNewswire/ – GreenLight Biosciences, Inc., the bio-performance company developing RNA-based solutions for agriculture and pharmaceutical applications, announced several new hires to augment its plant science R&D team: David Culley, head of fungicide innovation; Brian Manley, head of field development; Laurent Mézin, head of regulatory; Ken Narva, head of entomology; Cris Oppert, crop protection scientist; and Krishna Sridharan, head of data science. March 4, 2019 –– Press GreenLight Hires Commercial Team to Bring Targeted Biocontrol Products to Market MEDFORD, Mass., March 4, 2019 /PRNewswire/ – GreenLight Biosciences, Inc., the bio-performance company developing RNA-based solutions for agriculture and pharmaceutical applications, announced the hiring of three experienced agricultural leaders as the company’s commercial team. Ron Flannagan has been named director, technical portfolio management; Joe Hanson joins as director, market development; and Catie Lee will serve as senior marketing manager. January 8, 2019 –– Press GreenLight Announces $50 Million Funding Round MEDFORD, Mass., Jan. 8, 2019 /PRNewswire/ — GreenLight Biosciences, Inc., the bio-performance company developing RNA-based solutions for agriculture and pharmaceutical applications, announced today a $50 Million first closing of its latest funding round. The round was led by S2G Ventures, Baird Capital and Blue I/O. Several additional top-tier investors, including Continental Grain Company, Tao Capital Partners and Alexandria Venture Investments, joined the investor syndicate. The majority of existing GreenLight investors also participated in the oversubscribed round. July 24, 2018 –– Press GreenLight Welcomes New Chief Commercial Officer MEDFORD, Mass., July 24, 2018 /PRNewswire/ — GreenLight Biosciences, Inc., a biotechnology company developing RNA-based products for agricultural and pharmaceutical applications, today announced that Mick Messman has joined the Company as Chief Commercial Officer. Mr. Messman has over 20 years of global agricultural sales, marketing, business development and operations experience. Prior to joining GreenLight, he spent the last 5 years building and leading the seed applied and biologicals crop protection business at Corteva Agriscience, a division of DowDuPont. September 13, 2017 –– Press GreenLight Announces Series D Financing, Unveils RNA Strategy MEDFORD, Mass., Sept. 13, 2017 /PRNewswire/ — GreenLight Biosciences, Inc. announced today the completion of its $18 million Series D round of financing led by Fall Line Capital. S2G Ventures, Lewis and Clark Ventures, and Macro Capital Investments participated in the round, along with the majority of GreenLight\’s existing investors, including Kodiak Venture Partners, MLSCF, Syngenta Ventures and others. GreenLight is harnessing its Cell-Free Bioprocessing® platform to develop a portfolio of RNA-based products for use in agriculture. July 18, 2017 –– Press GreenLight to Present at the BIO World Congress on Industrial Biotechnology BOSTON, July 18, 2017 /PRNewswire/ — GreenLight Biosciences, Inc., a biotechnology company producing novel RNA-based products for agricultural, healthcare and other applications, today announced that management will present at the BIO World Congress on Industrial Biotechnology at the Palais des Congres in Montreal, Canada. The presentation entitled “A novel platform for development of double-stranded RNA agricultural products” will be delivered by Dr. Andrey J. Zarur, Chairman and CEO of GreenLight, on Wednesday July 26th at 10:30 a.m. ET. May 6, 2017 –– Blog The Economist: Cell-free biotech will make for better products Join the GreenLight Revolution Learn more about how GreenLight Biosciences is enabling innovative technologies to protect the health of people and the planet. We are always looking to meet new partners, new colleagues or anyone interested to learn more about RNA. CONTACT US JOIN OUR TEAM
January 26, 2021 –– Blog Financial Times: If Covid vaccines stop working, how quickly can drugmakers respond?
January 15, 2021 –– Blog STAT Opinion: Businesses across the vaccine supply chain must work together to make Covid-19 vaccines
December 4, 2020 –– Blog Financial Times: Vaccine manufacturing delays leave UK with fewer vaccines than hoped
November 12, 2020 –– Blog Fortune: If we don’t vaccinate the world quickly, our COVID efforts will be a waste
October 1, 2020 –– Press GreenLight Biosciences welcomes Charu Manocha as Chief People Officer BOSTON, October 1, 2020 – GreenLight Biosciences, Inc., an integrated life sciences company developing RNA-based products for plant health, human health and animal health, today announced Charu Manocha as the company’s new Chief People Officer.
September 15, 2020 –– Blog GreenLight Biosciences Receives $3.3 Million Grant BOSTON, Sept. 15, 2020 — GreenLight Biosciences has received a $3.3 million grant from the Bill & Melinda Gates Foundation to develop new mRNA-based gene therapies for Sickle Cell Disease and other global health challenges.
June 16, 2020 –– Press GreenLight Supercharges Efforts with $102M in Funding BOSTON, June 16, 2020 – GreenLight Biosciences today announced it has raised an oversubscribed $102 million round of funding from new and existing investors to rapidly expand production of its RNA products for agricultural and life sciences applications, including an expansion into new RNA-based therapies.
May 12, 2020 –– Press $17M Raised for COVID-19 Vaccine Manufacturing BOSTON, May 12, 2020 /PRNewswire/ — GreenLight Biosciences today announced it has closed an oversubscribed $17M special purpose funding round from new and existing investors to build out its scalable mRNA production capability targeting the production of billions of doses of COVID-19 vaccine.
September 19, 2019 –– Press GreenLight CEO Nominated for the Belisario Domínguez Medal of Honor MEDFORD, Mass., Sept. 19, 2019 /PRNewswire/ — Andrey Zarur, Ph.D., co-founder, president and CEO of GreenLight Biosciences, Inc., has been nominated as a candidate for the Medalla de Honor “Belisario Domínguez” del Senado de la República (Belisario Domínguez Medal of Honor) by the Mexican Senate.
June 11, 2019 –– Press GreenLight Welcomes Susan Keefe as CFO MEDFORD, Mass., June 11, 2019 /PRNewswire/ — GreenLight Biosciences, Inc., the bio-performance company developing RNA-based solutions for agriculture and pharmaceutical applications, welcomes Susan Keefe as chief financial officer to lead the company\’s financial strategy and facilitate its growth plan.
May 31, 2019 –– Press GreenLight Boosts R+D Capabilities with Key Hires MEDFORD, Mass., May 31, 2019 /PRNewswire/ – GreenLight Biosciences, Inc., the bio-performance company developing RNA-based solutions for agriculture and pharmaceutical applications, announced several new hires to augment its plant science R&D team: David Culley, head of fungicide innovation; Brian Manley, head of field development; Laurent Mézin, head of regulatory; Ken Narva, head of entomology; Cris Oppert, crop protection scientist; and Krishna Sridharan, head of data science.
March 4, 2019 –– Press GreenLight Hires Commercial Team to Bring Targeted Biocontrol Products to Market MEDFORD, Mass., March 4, 2019 /PRNewswire/ – GreenLight Biosciences, Inc., the bio-performance company developing RNA-based solutions for agriculture and pharmaceutical applications, announced the hiring of three experienced agricultural leaders as the company’s commercial team. Ron Flannagan has been named director, technical portfolio management; Joe Hanson joins as director, market development; and Catie Lee will serve as senior marketing manager.
January 8, 2019 –– Press GreenLight Announces $50 Million Funding Round MEDFORD, Mass., Jan. 8, 2019 /PRNewswire/ — GreenLight Biosciences, Inc., the bio-performance company developing RNA-based solutions for agriculture and pharmaceutical applications, announced today a $50 Million first closing of its latest funding round. The round was led by S2G Ventures, Baird Capital and Blue I/O. Several additional top-tier investors, including Continental Grain Company, Tao Capital Partners and Alexandria Venture Investments, joined the investor syndicate. The majority of existing GreenLight investors also participated in the oversubscribed round.
July 24, 2018 –– Press GreenLight Welcomes New Chief Commercial Officer MEDFORD, Mass., July 24, 2018 /PRNewswire/ — GreenLight Biosciences, Inc., a biotechnology company developing RNA-based products for agricultural and pharmaceutical applications, today announced that Mick Messman has joined the Company as Chief Commercial Officer. Mr. Messman has over 20 years of global agricultural sales, marketing, business development and operations experience. Prior to joining GreenLight, he spent the last 5 years building and leading the seed applied and biologicals crop protection business at Corteva Agriscience, a division of DowDuPont.
September 13, 2017 –– Press GreenLight Announces Series D Financing, Unveils RNA Strategy MEDFORD, Mass., Sept. 13, 2017 /PRNewswire/ — GreenLight Biosciences, Inc. announced today the completion of its $18 million Series D round of financing led by Fall Line Capital. S2G Ventures, Lewis and Clark Ventures, and Macro Capital Investments participated in the round, along with the majority of GreenLight\’s existing investors, including Kodiak Venture Partners, MLSCF, Syngenta Ventures and others. GreenLight is harnessing its Cell-Free Bioprocessing® platform to develop a portfolio of RNA-based products for use in agriculture.
July 18, 2017 –– Press GreenLight to Present at the BIO World Congress on Industrial Biotechnology BOSTON, July 18, 2017 /PRNewswire/ — GreenLight Biosciences, Inc., a biotechnology company producing novel RNA-based products for agricultural, healthcare and other applications, today announced that management will present at the BIO World Congress on Industrial Biotechnology at the Palais des Congres in Montreal, Canada. The presentation entitled “A novel platform for development of double-stranded RNA agricultural products” will be delivered by Dr. Andrey J. Zarur, Chairman and CEO of GreenLight, on Wednesday July 26th at 10:30 a.m. ET.